uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005
Show others and affiliations
2008 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 155, no 5, 829-40 p.Article in journal (Refereed) Published
Abstract [en]

In July 2005, leaders from academia, government, and industry convened in Washington, DC, to discuss key issues in the development of antithrombotic treatments for atrial fibrillation (AF). In addition to summarizing available data on the relative benefits and risks of currently available therapies in diverse clinical practice settings, we reviewed designs of ongoing trials and registries, focusing on areas of methodological controversy and uncertainty. Participants in this meeting described the growing burden of AF, summarized the data showing effectiveness of warfarin for prevention of stroke in AF, and noted that warfarin is both underused and poorly monitored and adjusted in general practice. There was consensus that there is an important unmet clinical need for better treatment of patients with AF at risk of stroke, including alternatives to warfarin that address its limitations. Comparative noninferiority trials to develop alternatives to warfarin must include warfarin management that is at least as good as that provided in historical trials. There was agreement that noninferiority trials can be done based on historical warfarin trials, and that placebo-controlled trials focused on patients not receiving warfarin in general practice can provide important information as well. Statistical principles for noninferiority in this setting were discussed, and a standard approach was proposed. A majority of clinical trial representatives suggested that large, simple, open-label trials would provide the most meaningful information relevant to future practice, but regulators cautioned that, in such a simple trial, one needs to ensure that the control group does at least as well as the historical controls for the noninferiority design to be interpretable. With this summary document, we hope to provide a helpful resource for future drug development for AF.

Place, publisher, year, edition, pages
2008. Vol. 155, no 5, 829-40 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-104771DOI: 10.1016/j.ahj.2008.01.023ISI: 000256001500006PubMedID: 18440329OAI: oai:DiVA.org:uu-104771DiVA: diva2:220130
Available from: 2009-05-29 Created: 2009-05-29 Last updated: 2012-07-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Wallentin, Lars
By organisation
Department of Medical Sciences
In the same journal
American Heart Journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 206 hits
ReferencesLink to record
Permanent link

Direct link